CClinicalTrials.gg
Sign In
Status unknownNCT02156024Updated Jun 6, 2014

The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension

A Phase 4 interventional study of Gastrodia and Uncaria Drink in Masked Hypertension, sponsored by Shanghai Institute of Hypertension. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Shanghai Institute of Hypertension · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is

  1. To determine whether the Gastrodia and Uncaria Drink is effective in the treatment of masked hypertensive patients below 70 years.
  2. To find out the suitable groups for the Gastrodia and Uncaria Drink treatment.
02

Conditions studied

  • Masked Hypertension

Browse trials for

Keywords

  • clinical trials
  • Gastrodia and Uncaria Drink
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's planned enrollment of 400 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Shanghai Institute of Hypertension is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • age between 18 to 70 years
  • didn't use any anti-hypertension drugs within 2 weeks
  • stage 1 masked hypertensive patients, which means clinic blood pressure\<140/90 mmHg,however the daytime(8:00-18:00) 24h ambulatory blood pressure between 135/85 and 150/95mmHg
  • be willing to participate in the trials and able to finish clinic visit

Exclusion criteria

Exclusion Criteria:

  • secondary hypertension
  • be allergic to the clinical trial medicine
  • occurrence of stroke, CKD, myocardial infarction within 2 years
  • dysfunction of liver or kidney and fundus hemorrhage
  • arrhythmia
  • ALT, AST, TBL upper the twice of normal range, Scr≥2.0mg/dl, K+≥5.5mmol/L, Urine protein≥2+
  • psychiatric disorders
  • pregnant, breastfeeding
  • other serious conditions in which is not fit for the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    placebo drink, 1 dose at a time, twice a day, duration: 4 weeks

  • Active comparator
    Gastrodia and Uncaria Drink

    Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks

    Drug: Gastrodia and Uncaria Drink

Interventions

  • DrugGastrodia and Uncaria Drink

    Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks

    Also known as: tianma gouteng drink

06

What researchers measure

Primary outcomes

  1. blood pressure

    Time frame: March 1,2015

07

Study locations

1 of 1 sites recruiting
  • Ruijin Hospital
    Shanghai, Shanghai 200025, China
    • Yan Li, doctor · Contact · liyanshcn@yahoo.com · 021-64370045
    • Yan Li, docter · Principal investigator
    Recruiting
08

References and documents

Publications

  • Zhang DY, Cheng YB, Guo QH, Shan XL, Wei FF, Lu F, Sheng CS, Huang QF, Yang CH, Li Y, Wang JG. Treatment of Masked Hypertension with a Chinese Herbal Formula: A Randomized, Placebo-Controlled Trial. Circulation. 2020 Nov 10;142(19):1821-1830. doi: 10.1161/CIRCULATIONAHA.120.046685. Epub 2020 Oct 6. PubMed 33019798 ↗
  • Wei FF, Li Y, Zhang L, Shan XL, Cheng YB, Wang JG, Yang CH, Staessen JA. Persistence of Masked Hypertension in Chinese Patients. Am J Hypertens. 2016 Mar;29(3):326-31. doi: 10.1093/ajh/hpv106. Epub 2015 Jul 6. PubMed 26150543 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02156024
Lead sponsor
Shanghai Institute of Hypertension
Responsible party
Cheng Yibang (master, Shanghai Institute of Hypertension) — Principal investigator
First posted
Jun 5, 2014
Start date
Mar 2014
Primary completion
Mar 2015 (estimated)
Last update
Jun 6, 2014

Study contacts

Yan Li, doctor
Contact
liyanshcn@yahoo.com
021-64370045 ext. 663228
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension→

Other studies from this sponsor

Shanghai Institute of Hypertension

Start the discussion